Literature DB >> 24003656

Red yeast rice for dysipidemia.

Shariq Shamim1, Firas J Al Badarin, James J DiNicolantonio, Carl J Lavie, James H O'Keefe.   

Abstract

Red yeast rice is an ancient Chinese food product that contains monacolins, chemical substances that are similar to statins in their mechanisms of action and lipid lowering properties. Several studies have found red yeast rice to be moderately effective at improving the lipid profile, particularly for lowering the low-density lipoprotein cholesterol levels. One large randomized controlled study from China found that red yeast rice significantly improved risk of major adverse cardiovascular events and overall survival in patients following myocardial infarction. Thus, red yeast rice is a potentially useful over-the-counter cholesterol-lowering agent. However, many red yeast rice formulations are non-standardized and unregulated food supplements, and there is a need for further research and regulation of production.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24003656      PMCID: PMC6179893     

Source DB:  PubMed          Journal:  Mo Med        ISSN: 0026-6620


  33 in total

Review 1.  The role of red yeast rice for the physician.

Authors:  Ram Y Gordon; David J Becker
Journal:  Curr Atheroscler Rep       Date:  2011-02       Impact factor: 5.113

2.  Marked variability of monacolin levels in commercial red yeast rice products: buyer beware!

Authors:  Ram Y Gordon; Tod Cooperman; William Obermeyer; David J Becker
Journal:  Arch Intern Med       Date:  2010-10-25

3.  Myopathies associated with red yeast rice and liquorice: spontaneous reports from the Italian Surveillance System of Natural Health Products.

Authors:  Francesco Lapi; Eugenia Gallo; Sara Bernasconi; Michele Vietri; Francesca Menniti-Ippolito; Roberto Raschetti; Luigi Gori; Fabio Firenzuoli; Alessandro Mugelli; Alfredo Vannacci
Journal:  Br J Clin Pharmacol       Date:  2008-05-21       Impact factor: 4.335

4.  Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients--the PRIMO study.

Authors:  Eric Bruckert; Gilles Hayem; Sylvie Dejager; Caroline Yau; Bernard Bégaud
Journal:  Cardiovasc Drugs Ther       Date:  2005-12       Impact factor: 3.727

5.  The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators.

Authors:  F M Sacks; M A Pfeffer; L A Moye; J L Rouleau; J D Rutherford; T G Cole; L Brown; J W Warnica; J M Arnold; C C Wun; B R Davis; E Braunwald
Journal:  N Engl J Med       Date:  1996-10-03       Impact factor: 91.245

6.  Rosuvastatin 5 and 10 mg/d: a pilot study of the effects in hypercholesterolemic adults unable to tolerate other statins and reach LDL cholesterol goals with nonstatin lipid-lowering therapies.

Authors:  Charles J Glueck; Dawit Aregawi; Mahlia Agloria; Qasim Khalil; Magdalena Winiarska; Jitender Munjal; Srikanth Gogineni; Ping Wang
Journal:  Clin Ther       Date:  2006-06       Impact factor: 3.393

7.  Statins and musculoskeletal conditions, arthropathies, and injuries.

Authors:  Ishak Mansi; Christopher R Frei; Mary Jo Pugh; Una Makris; Eric M Mortensen
Journal:  JAMA Intern Med       Date:  2013-07-22       Impact factor: 21.873

Review 8.  Toward "pain-free" statin prescribing: clinical algorithm for diagnosis and management of myalgia.

Authors:  Terry A Jacobson
Journal:  Mayo Clin Proc       Date:  2008-06       Impact factor: 7.616

9.  Prevalence of and risk factors for autopsy-determined atherosclerosis among US service members, 2001-2011.

Authors:  Bryant J Webber; Peter G Seguin; Daniel G Burnett; Leslie L Clark; Jean L Otto
Journal:  JAMA       Date:  2012-12-26       Impact factor: 56.272

10.  Tolerability of red yeast rice (2,400 mg twice daily) versus pravastatin (20 mg twice daily) in patients with previous statin intolerance.

Authors:  Steven C Halbert; Benjamin French; Ram Y Gordon; John T Farrar; Kathryn Schmitz; Patti B Morris; Paul D Thompson; Daniel J Rader; David J Becker
Journal:  Am J Cardiol       Date:  2009-11-26       Impact factor: 2.778

View more
  2 in total

1.  Recent publications by ochsner authors.

Authors: 
Journal:  Ochsner J       Date:  2013

Review 2.  Natural Bioactive Compounds Useful in Clinical Management of Metabolic Syndrome.

Authors:  Annalisa Noce; Manuela Di Lauro; Francesca Di Daniele; Anna Pietroboni Zaitseva; Giulia Marrone; Patrizia Borboni; Nicola Di Daniele
Journal:  Nutrients       Date:  2021-02-16       Impact factor: 5.717

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.